8-Isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: A pilot study

Inflammation Research

Volumn 61, Issue 8, 2012, Pages 809-816

  Sciascia, Savino ^a   Roccatello, Dario ^a   Bertero, Maria Tiziana ^b   Di Simone, Debora ^a   Cosseddu, Domenico ^b   Vaccarino, Antonella ^c   Bazzan, Mario ^c   Rossi, Daniela ^a   Garcia Fernandez, Cesar ^d   Ceberio, Leticia ^e   Stella, Stefania ^c   Menegatti, Elisa ^f   Baldovino, Simone ^a  

^a Centro di Ricerche di Immunopatologia e Documentazione Su Malattie Rare (CMID)   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

^c S GIOVANNI BOSCO HOSPITAL   (Italy)

^d Medicina Interna   (Spain)

^e HOSPITAL TXAGORRITXU   (Spain)

^f UNIVERSITY OF TURIN   (Italy)

Author keywords

Antiphospholipid syndrome; Inflammation; Oxidative stress

Indexed keywords

8 ISOPROSTANE; AMYLOID A PROTEIN; BETA2 GLYCOPROTEIN 1 ANTIBODY; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROSTAGLANDIN E2;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOASSAY; INFLAMMATION; MALE; MORBIDITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PILOT STUDY; PROSTAGLANDIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DINOPROST; DINOPROSTONE; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PILOT PROJECTS; SERUM AMYLOID A PROTEIN;

EID: 84865127527     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0468-0     Document Type: Article

References (43)

1. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004;109(22):2698-704. (Pubitemid 38737913)
2. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol. 2006;2(2): 99-106. (Pubitemid 43239209)
3. Jara LJ, Medina G, Vera-Lastra O, Shoenfeld Y. Atherosclerosis and antiphospholipid syndrome. Clin Rev Allergy Immunol. 2003;25(1):79-88.
4. Soltesz P, Szekanecz Z, Kiss E, Shoenfeld Y. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev. 2007; 6(6):379-86. (Pubitemid 46810399)
5. Ames PR, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis. 2005;64(2):315-7. (Pubitemid 40193636)
6. Plazak W, Pasowicz M, Kostkiewicz M, Podolec J, Tomkiewicz- Pajak L, Musial J, et al. Influence of chronic inflammation and autoimmunity on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients. Inflamm Res. 2011;60(10):973-80.
7. Ahmed K, Vianna JL, Khamashta MA, Hughes GR. IL-2, IL-6 and TNF levels in primary antiphospholipid syndrome. Clin Exp Rheumatol. 1992;10(5):503.
8. Forastiero RR, Martinuzzo ME, de Larranaga GF. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus. 2005;14(2):129-36. (Pubitemid 40327663)
9. Hamid C, Norgate K, D'Cruz DP, Khamashta MA, Arno M, Pearson JD, et al. Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel proinflammatory genes potentially involved in primary antiphospholipid syndrome. Ann Rheum Dis. 2007;66(8):1000-7. (Pubitemid 47122310)
10. Ames PR, Tommasino C, Brancaccio V, Ciampa A. C-reactive protein in primary antiphospholipid syndrome. J Rheumatol. 2007;34(3):650.
11. Sailer T, Vormittag R, Pabinger I, Vukovich T, Lehr S, Quehenberger P, et al. Inflammation in patients with lupus anticoagulant and implications for thrombosis. J Rheumatol. 2005;32(3):462-8. (Pubitemid 40381416)
12. Sidelmann JJ, Sjoland JA, Gram J, Bertelsen V, Mourits- Andersen T, Munster H, et al. Lupus anticoagulant is significantly associated with inflammatory reactions in patients with suspected deep vein thrombosis. Scand J Clin Lab Invest. 2007;67(3): 270-9. (Pubitemid 46643382)
13. Miesbach W, Gokpinar B, Gilzinger A, Claus D, Scharrer I. Predictive role of hs-C-reactive protein in patients with antiphospholipid syndrome. Immunobiology. 2005;210(10):755-60. (Pubitemid 41683859)
14. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA. 2002;99(20):13043-8.
15. Tabuchi M, Inoue K, Usui-Kataoka H, Kobayashi K, Teramoto M, Takasugi K, et al. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res. 2007;48(4):768-81. (Pubitemid 46557882)
16. DE O'Connor ME, Coleman MC. Stereochemical course of the auto-oxidative cyclization of lipid hydroperoxides to prostaglandin- like signal peroxides. J Am Chem Soc. 1984;106: 3577-84. (Pubitemid 14609840)
17. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radicalcatalyzed mechanism. Proc Natl Acad Sci USA. 1990;87(23): 9383-7. (Pubitemid 120030630)
18. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
19. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7:1737-40.
20. Thiagarajan P, Pengo V, Shapiro S. The use of dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood. 1986;68:869-74. (Pubitemid 17183845)
21. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7(6):330-9.
22. Lambrianides A, Carroll CJ, Pierangeli SS, Pericleous C, Branch W, Rice J, et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol. 2010;184(12):6622-8.
23. Agar C, van Os GM, Morgelin M, Sprenger RR, Marquart JA, Urbanus RT, et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010;116(8):1336-43.
24. Raschi E, Testoni C, Bosisio D, Borghi MO, Koike T, Mantovani A, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood. 2003;101(9):3495-500. (Pubitemid 36857933)
25. Espinola RG, Liu X, Colden-Stanfield M, Hall J, Harris EN, Pierangeli SS. E-Selectin mediates pathogenic effects of antiphospholipid antibodies. J Thromb Haemost. 2003;1(4): 843-8.
26. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005;112(21):3337-47. (Pubitemid 43739380)
27. Montuschi P, Barnes P, Roberts LJ 2nd. Insights into oxidative stress: the isoprostanes. Curr Med Chem. 2007;14(6):703-17. (Pubitemid 46477722)
28. Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714-8.
29. Ruffatti A, Tonello M, Cavazzana A, Bagatella P, Pengo V. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res. 2009;123(3):482-7.
30. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005;93(6):1147-52. (Pubitemid 40823521)
31. Pengo V. APS-controversies in diagnosis and management, critical overview of current guidelines. Thromb Res. 2011;127(Suppl 3): S51-2.
32. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol. 1997;17(11):2309-15. (Pubitemid 28015962)
33. Morrow JD, Minton TA, Roberts LJ 2nd. The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/ endoperoxide receptor antagonist. Prostaglandins. 1992;44(2): 155-63.
34. Pratico D, Smyth EM, Violi F, FitzGerald GA. Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. J Biol Chem. 1996;271(25):14916-24.
35. Lynch SM, Morrow JD, Roberts LJ 2nd, Frei B. Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. J Clin Invest. 1994;93(3):998-1004. (Pubitemid 24087149)
36. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271(52):33157-60. (Pubitemid 27010118)
37. Wang Z, Ciabattoni G, Creminon C, Lawson J, Fitzgerald GA, Patrono C, et al. Immunological characterization of urinary 8-epiprostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther. 1995;275(1):94-100.
38. Pratico D, FitzGerald GA. Generation of 8-epiprostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase- 2. J Biol Chem. 1996;271(15):8919-24.
39. Kloner RA, Przyklenk K, Whittaker P. Deleterious effects of oxygen radicals in ischemia/reperfusion. Resolved and unresolved issues. Circulation. 1989;80(5):1115-27. (Pubitemid 19282500)
40. Fabre JE, Nguyen M, Athirakul K, Coggins K, McNeish JD, Austin S, et al. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest. 2001;107(5):603-10. (Pubitemid 32205181)
41. Meroni PL, Raschi E, Testoni C, Tincani A, Balestrieri G, Molteni R, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 2001;44(12):2870-8. (Pubitemid 34016207)
42. Ferrara DE, Liu X, Espinola RG, Meroni PL, Abukhalaf I, Harris EN, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum. 2003;48(11):3272-9. (Pubitemid 37409342)
43. Proudfoot J, Barden A, Mori TA, Burke V, Croft KD, Beilin LJ, et al. Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem. 1999;272(2):209-15. (Pubitemid 29364984)